BA/BE Studies for Early Termination [Two-Stage / GS Designs]

posted by ElMaestro  – Denmark, 2015-09-22 15:35 (3433 d 20:52 ago) – Posting: # 15444
Views: 5,247

Hi balakotu,

❝ We are planning to conduct one "Replicate 4-period" bio-equivalence study with 70 subjects.

❝ After completion of clinical phase we will analyze only 40 subjects.

❝ If 40 subject’s data is shown bio-equivalent then we will stop the analysis of remaining 30 subjects. If the data is predictable then we will analyze remaining 30 subjects.


This sounds like a two-stage approach. If you allow yourself two chances of showing BE at the usual alpha of 5% then some regulators may protest due to overall type I error inflation. Check publications by Diane Potvin and coworkers for ways forward which retain control of the error.
In addition, I think you should use all available data: If you have data from 70 subjects, then I believe all 70 subjects should be analysed to avoid ethics issues.

"Replicate 4-period" in connection to two-stage designs is so far uncharted territory. I don't recommend trotting down that avenue.

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,380 posts in 4,914 threads, 1,665 registered users;
45 visitors (0 registered, 45 guests [including 10 identified bots]).
Forum time: 11:28 CET (Europe/Vienna)

When people learn no tools of judgment
and merely follow their hopes,
the seeds of political manipulation are sown.    Stephen Jay Gould

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5